There were no significant associations between NAFLD and liver enzymes with the risk of CVD incidence of subgroups, except for ALT levels and MI incidence (HR: 1.01 [1.01, 1.02], P=0.005) and ALK-P levels with CHF (HR: 1.02 [1.01, 1.04], P=0.012) (Table 2). Here, ALK is linked to metabolic dysfunction-associated steatotic liver disease.